Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 20, 2015

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

Massachusetts		0-17999		04-2726691
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

ITEM 8.01 — OTHER EVENTS

 

On May 20, 2015, Novartis Institutes for BioMedical Research, Inc. (“Novartis”) notified ImmunoGen, Inc. (also referred to as “our”) that it had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing our antibody-drug conjugate (ADC) technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5 million milestone payment to ImmunoGen.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	ImmunoGen, Inc.
	(Registrant)
Date: May 21, 2015	/s/ David B. Johnston
	David B. Johnston
	Executive Vice President and Chief Financial Officer

 

2

---